ClinicalTrials.gg

Program

ABBV-859

A development code.

In AbbVie's pipeline, IL-23R. Its studies are led by AbbVie.

Furthest: phase 1, since Jul 27, 20261 company-led study, 1 open or runningNext primary completion: Feb 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVie11 open or runningphase 1since Jul 27, 2026Jul 27, 2026Feb 2027phase 1 · NCT07736638
  • Named in AbbVie’s own pipeline as ABBV-859, phase 1, as of Jul 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 27, 2026First study: phase 1 study in Healthy VolunteerFirst studyNCT07736638 · 64 planned · United States

Ahead

  1. Feb 2027Primary completion: phase 1 study in Healthy VolunteerNCT07736638

TargetBeta

“IL-23R”the company's pipeline, read by Claude · source

Other programs on IL23R

ProgramCompanyFurthest phaseStudies
HS-20118Hansoh Pharmaceutical Groupphase 24

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07736638Healthy Volunteer · United States1RecruitingFeb 202764

How it is read

Names in the registry

  • “ABBV-859”, 2 entries

Codes read as this program: ABBV859.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.